Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis - Procalcitonin, Presepsin. Correlation With Blood Culture and Detection of Infection by Molecular Biological Methods

NCT03314831 is registered in ClinicalTrials.gov with Charles University, Czech Republic as lead sponsor.

NCT NCT03314831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03314831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis - Procalcitonin, Presepsin. Correlation With Blood Culture and Detection of Infection by Molecular Biological Methods
Lead sponsor
Charles University, Czech Republic
Phase
Observational
Overall status
Completed
Start date
October 24, 2017
Completion date
December 31, 2022
Enrollment
282 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis syndrome, systemic inflammatory response syndrome